From Interchangeability To Invisibility: FDA Wipes Designation From Biosimilar Labels
New Draft Guidance Urges Removal Of Interchangeability Designation From Biosimilar Labeling
Amid continuing stakeholder confusion over the meaning and significance of the US FDA’s interchangeability designation for biosimilars, the agency has now recommended omitting altogether details of interchangeability from biosimilar labels.
